2017 American Transplant Congress
Risk of Primary Central Nervous System Lymphoma in Solid Organ Transplant Recipients.
National Cancer Institute, Bethesda, MD
Background: Risk of primary central nervous system lymphoma (PCNSL) is greatly increased in immunosuppressed HIV-infected people. Case series describe PCNSL in solid organ transplant (SOT)…2017 American Transplant Congress
Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy.
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this…2017 American Transplant Congress
BK Polyoma Virus and Malignancy: Cause or Co-Incidence?
Henry Ford Transplant Institute, Detroit, MI
BackgroundThe WHO agency for cancer research has classified BKV as "possibly carcinogenic".The etiological role of BKV in human cancer, however,remains controversial.We present 5 cases of…2017 American Transplant Congress
Three Induction Therapies on Patients with Delayed Graft Function After Kidney Transplantation, a Three-Year Outcome Analysis.
Departments of Medicine and Surgery, Tulane University School of Medicine, New Orleans, LA
We compare the 3-year outcomes of induction therapies with either methylprednisolone (group 1, n=58), basiliximab (group 2, n=56) or alemtuzumab (group 3, n=98) in primary…2017 American Transplant Congress
The Impact of Hepatitis C Treatment on GFR and Immunosuppression in Renal Transplant Recipients.
University of Maryland Medical Center, Baltimore, MD
Background: Renal transplant recipients (RTRs) with HCV are at an increased risk of graft rejection, making treatment of HCV in this population of the utmost…2017 American Transplant Congress
Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).
Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…2017 American Transplant Congress
Evaluating T Cell Repopulation Post Alemtuzumab Induction with a Belatacept-Based Regimen.
Department of Surgery, Duke University, Durham, NC
We reported that alemtuzumab induction followed by belatacept-sirolimus based immunosuppression effectively prevents costimulation blockade resistant rejection (CoBRR). This study investigates the phenotypic characteristics of repopulating…2017 American Transplant Congress
Alemtuzumab Induction and Belatacept Maintenance in Marginal Pathology Renal Allografts.
University of Maryland, Baltimore
Background: The potential for improved outcomes with CNI avoidance may be important for kidneys with an increased likelihood of impaired graft function. We performed a…2017 American Transplant Congress
Clinical and Pathologic Characteristics of Acute Rejection After Alemtuzumab Induction in Kidney Transplant Recipients.
Background: Alemtuzumab induction (AZI) can be used for early steroid withdrawal in kidney transplant (KTx) recipients. There is evidence that AZI-induced lymphocyte depletion leads to…2017 American Transplant Congress
The Outcome of 0 Mismatch Kidney in Pediatric Population with High Immunologic. The Impact of Induction Therapy. An Analysis of UNOS Database.
Surgery, State University New York, Syracuse, NY
Background: 0 mismatch kidneys have superior outcomes in primary transplant recipient. We performed Analysis UNOS database to determine the outcome of high PRA transplant pediatric…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 31
- Next Page »